Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for non-small cell lung cancer (NSCLC), a type of lung cancer. The study involves several medications, including AZD6738 (also known as ceralasertib), DS-8201a (also known as trastuzumab deruxtecan), mycophenolate mofetil, infliximab, and IMFINZI (also known as durvalumab). These medications are being tested to see how effective they are in treating patients whose cancer has progressed after receiving previous treatments that included anti-PD-1 or PD-L1 therapies.

The purpose of the study is to evaluate the effectiveness of each treatment by looking at how well the cancer responds. Participants in the study will receive one or more of these medications, which may be given as tablets, infusions, or capsules, depending on the specific treatment. Some participants may receive a placebo. The study will monitor the participants over a period of time to observe the effects of the treatments on their cancer.

Throughout the study, participants will undergo regular assessments to track the progress of their cancer and any changes in their health. The study aims to gather information on how these treatments can help manage NSCLC, especially in cases where the cancer has not responded to previous therapies. This research is important for developing new treatment options for patients with this type of lung cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age, type of lung cancer, and previous treatments.

    A new tumor biopsy may be required unless a recent sample is available.

  2. Step 2

    Treatment initiation

    The study involves multiple medications, each administered differently. The medications include ceralasertib (AZD6738) taken orally as a film-coated tablet, trastuzumab deruxtecan (DS-8201a) given intravenously as a solution for infusion, mycophenolate mofetil taken orally, infliximab administered intravenously, and durvalumab (IMFINZI) given intravenously as a concentrate for infusion.

    The specific medication and dosage depend on individual treatment plans.

  3. Step 3

    Treatment monitoring

    Regular monitoring of treatment response is conducted using imaging and other assessments to measure tumor size and progression.

    The primary goal is to evaluate the objective response rate, which indicates how well the cancer responds to the treatment.

  4. Step 4

    Evaluation of treatment outcomes

    Secondary outcomes include overall survival, disease control rate, best percentage change in tumor size, duration of response, and progression-free survival.

    These outcomes help determine the effectiveness of the treatment over time.

  5. Step 5

    Completion of the study

    The study is estimated to conclude by August 13, 2024.

    Upon completion, final assessments are conducted to evaluate the overall impact of the treatment.

Who can join the trial?

7 criteria

  • Must be at least 18 years old when signing the consent form.
  • Must have a confirmed diagnosis of **non-small cell lung cancer (NSCLC)** that is either spreading or has come back after treatment.
  • Eligible for further treatment after having received specific therapies, including an **anti PD-1/PD-L1 therapy** and a **platinum-doublet regimen**. These are types of cancer treatments. The cancer must have worsened after these treatments.
  • Must be able to provide a new sample of the tumor for testing. In some cases, a recent sample taken within the last 24 months may be acceptable.
  • Must have a **performance status** of 0 to 1, which means being fully active or having some symptoms but still able to carry out light work. Must also have a life expectancy of at least 12 weeks.
  • Must have at least one tumor that can be measured accurately. If a tumor was treated with radiation before, it can still be measured if it has grown since then.
  • For women who can have children, there must be proof of being post-menopausal or a negative pregnancy test.

Who cannot join the trial?

8 criteria

  • Patients who have a different type of cancer other than non-small cell lung cancer (NSCLC).
  • Individuals who are not within the specified age range for the study.
  • People who are not able to give informed consent or understand the study requirements.
  • Patients who are pregnant or breastfeeding.
  • Individuals with other serious health conditions that might interfere with the study.
  • Patients who have participated in another clinical trial recently.
  • Individuals who are allergic to the study medication or its ingredients.
  • Patients who are currently receiving treatment that might conflict with the study medication.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Anti-PD-1/PD-L1 Therapy

    is a type of cancer treatment that helps the immune system fight cancer. It works by blocking the PD-1 or PD-L1 proteins, which can prevent the immune system from attacking cancer cells. This therapy is used in patients with non-small cell lung cancer who have already been treated with similar therapies but need further treatment due to disease progression.

  • Biomarker-Directed Therapy

    involves using specific biological markers found in the patient's cancer cells to guide treatment decisions. This approach aims to tailor the treatment to the individual characteristics of the cancer, potentially improving the effectiveness of the therapy.

  • Multi-Drug Therapy

    refers to the use of more than one medication to treat cancer. This approach can help target different pathways that cancer cells use to grow and survive, potentially increasing the chances of treatment success.

What is already known about the treatment

Hudson – This medication is administered orally and is currently being studied in clinical trials for its effectiveness in treating patients with non-small cell lung cancer (NSCLC) who have not responded to previous anti-PD-1/PD-L1 therapies. It is in the experimental phase and is not yet widely recognized in medical literature. The main therapeutic indication is for NSCLC, aiming to improve the objective response rate in patients. At the molecular level, it works by targeting specific biomarkers associated with cancer cell growth, although the exact mechanism is still under investigation. It falls under the pharmacological classification of targeted cancer therapies.

Investigated diseases

Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that includes several subtypes such as adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. It is the most common type of lung cancer, accounting for about 85% of all cases. NSCLC typically grows and spreads more slowly than small cell lung cancer. The disease often begins in the cells lining the air passages and can spread to other parts of the body. Symptoms may include a persistent cough, chest pain, and shortness of breath. As the disease progresses, it may lead to more severe respiratory issues and other systemic symptoms.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2023-509004-15-00Protocol codeD6185C00001Estimated enrolment315 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.